|
|
|
|
||
Re: REDUCE IT trial design and rationale published in Clinical Cardiology Yes- I'll hold and wait. I just think the stock is so manipulated. How do you explain that the share price was at 15 before the approval of V, the FDA screws the whole thing up in a TOTALLY UNETHICAL way, the stock tanks to below one, AMRN fights it and wins, and the pps can just about hold 3. It's just ridiculous. You think this is normal? |
return to message board, top of board |